59 Result(s)

Article

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

The nonrandom recurrent nature of chromosome abnormalities in myeloma suggests a role for them in disease pathogenesis. We performed a careful cytogenetic analysis of patients with abnormal karyotypes (n = 254), ...

C S Debes-Marun, G W Dewald, S Bryant, E Picken, R Santana-Dávila… in Leukemia (2003)

Article

Thalidomide as initial therapy for early-stage myeloma

Patients with early-stage myeloma are typically observed without therapy until symptomatic disease occurs. However, they are at high risk of progression to symptomatic myeloma, with a median time to progressio...

S V Rajkumar, M A Gertz, M Q Lacy, A Dispenzieri, R Fonseca, S M Geyer… in Leukemia (2003)

Article

Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age

The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patie...

D E Reece, C Bredeson, W S Pérez, S Jagannath, M J Zhang… in Bone Marrow Transplantation (2003)

Article

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma

Bone marrow (BM) angiogenesis is increased in multiple myeloma and is an important prognostic factor for survival. Previous studies have shown that BM angiogenesis does not change following chemotherapy or ste...

S Kumar, T E Witzig, A Dispenzieri, M Q Lacy, L E Wellik, R Fonseca, J A Lust… in Leukemia (2004)

Article

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

Autologous stem cell transplant (SCT) improves survival in multiple myeloma (MM) and remains the standard of care for eligible patients. Nearly a third of patients with newly diagnosed MM fail initial therapy ...

S Kumar, M Q Lacy, A Dispenzieri, S V Rajkumar, R Fonseca… in Bone Marrow Transplantation (2004)

Article

Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy

Bone marrow (BM) angiogenesis is increased in multiple myeloma and is an important prognostic factor. However, prior studies were mainly done on patients receiving conventional chemotherapy and there is limite...

S Kumar, M A Gertz, A Dispenzieri, M Q Lacy, L A Wellik… in Bone Marrow Transplantation (2004)

Article

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

Given the survival advantage, high-dose therapy (HDT) remains the standard of care for patients with multiple myeloma eligible for the procedure. For those undergoing HDT, initial therapy aimed at reducing tum...

S Kumar, M Q Lacy, A Dispenzieri, S V Rajkumar, R Fonseca… in Bone Marrow Transplantation (2004)

Article

Five decades of therapy for multiple myeloma: a paradigm for therapeutic models

R A Kyle in Leukemia (2005)

Article

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

Chromosomal hyperdiploidy is the defining genetic signature in 40–50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM p...

W J Chng, R Santana-Dávila, S A Van Wier, G J Ahmann, S M Jalal, P L Bergsagel… in Leukemia (2006)

Article

Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma

CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our...

T Ise, S Nagata, R J Kreitman, W H Wilson, A S Wayne, M Stetler-Stevenson… in Leukemia (2007)

Article

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such variation. These findings have broad implications for cou...

A K Stewart, P L Bergsagel, P R Greipp, A Dispenzieri, M A Gertz, S R Hayman… in Leukemia (2007)

Article

Autologous stem cell transplantation in the elderly including pre- and post-treatment options

Multiple myeloma (MM) is a disease of the elderly with a median age at diagnosis of 67 years in a referral population. High-dose chemotherapy (HDT) and autologous stem cell transplantation has been shown to im...

S K Kumar, S R Hayman, R A Kyle in Bone Marrow Transplantation (2007)

Article

Clinically relevant end points and new drug approvals for myeloma

This manuscript summarizes the recommendations of the American Society of Hematology/US Food and Drug Administration Workshop on Clinical Endpoints in Multiple Myeloma, which brought together clinical investig...

K C Anderson, R A Kyle, S V Rajkumar, A K Stewart, D Weber, P Richardson in Leukemia (2008)

Article

Genetic aberrations and survival in plasma cell leukemia

Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We repo...

R E Tiedemann, N Gonzalez-Paz, R A Kyle, R Santana-Davila, T Price-Troska… in Leukemia (2008)

Article

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

M A Hussein, F D Vrionis, R Allison, J Berenson, S Berven, E Erdem, S Giralt… in Leukemia (2008)

Article

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

To determine if the serum free light chain (FLC) ratio has prognostic value in patients with symptomatic multiple myeloma (MM), baseline serum samples from a well-characterized cohort of 790 newly diagnosed MM...

C L H Snozek, J A Katzmann, R A Kyle, A Dispenzieri, D R Larson, T M Therneau… in Leukemia (2008)

Article

Clinical and biological significance of RAS mutations in multiple myeloma

W J Chng, N Gonzalez-Paz, T Price-Troska, S Jacobus, S V Rajkumar, M M Oken… in Leukemia (2008)

Article

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

New systems have emerged for diagnosis, staging and response assessment in multiple myeloma (MM). The diagnostic and response criteria recommended are primarily derived from the International Myeloma Working G...

R A Kyle, S V Rajkumar in Leukemia (2009)

Article

Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

The international staging system (ISS) for multiple myeloma (MM) is a validated alternative to the Durie–Salmon staging system (DSS) for predicting survival at diagnosis. We compared these staging systems for ...

P N Hari, M-J Zhang, V Roy, W S Pérez, A Bashey, L B To, G Elfenbein… in Leukemia (2009)